Evidence map›Paper›PMID 39621267›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2025

Evaluation of Vaccinia Virus Infection in Mice Using Two-Reporter Recombinant Virus.

Aitor Nogales, Kevin Chiem, María M Lorenzo, Javier Rangel-Moreno, Maria de la Luz Garcia-Hernandez, Jun-Gyu Park, Rafael Blasco, Luis Martinez-Sobrido

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Aitor NogalesDepartment of Microbiology and Immunology, University of Rochester, Rochester, NY, USA.
Kevin ChiemDepartment of Microbiology and Immunology, University of Rochester, Rochester, NY, USA.
María M LorenzoDepartamento de Biotecnología, Centro Nacional Instituto de Investigación y Tecnología Agraria y Alimentaria (INIA, CSIC), Madrid, Spain.
Javier Rangel-MorenoDivision of Allergy/Immunology and Rheumatology, Department of Medicine, University of Rochester, Rochester, NY, USA.
Maria de la Luz Garcia-HernandezDivision of Allergy/Immunology and Rheumatology, Department of Medicine, University of Rochester, Rochester, NY, USA.
Jun-Gyu ParkDepartment of Microbiology and Immunology, University of Rochester, Rochester, NY, USA.
Rafael BlascoDepartamento de Biotecnología, Centro Nacional Instituto de Investigación y Tecnología Agraria y Alimentaria (INIA, CSIC), Madrid, Spain. blasco@inia.csic.es.
Luis Martinez-SobridoDepartment of Microbiology and Immunology, University of Rochester, Rochester, NY, USA. LMartinez@txbiomed.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The family Poxviridae comprises multiple viruses with large double-stranded (ds) DNA genomes that can infect numerous vertebrate and invertebrate hosts, including humans. The development of genetic engineering methods for Vaccinia virus (VACV), the prototypic member in the family, have allowed the manipulation of the genomes of poxviruses for the generation of recombinant (r)VACV expressing easily traceable luciferase and/or fluorescent reporter genes. These recombinant viruses have significantly contributed to progress in the field of poxvirus research and accelerated the development of novel prophylactic vaccines and therapeutic antiviral treatments. Recently, we described two reporter rVACV expressing luciferase (Nluc) and fluorescent (GFP or Scarlet) proteins to easily track viral infections in different systems, overcoming the limitations associated with the use of rVACV expressing a single luciferase or fluorescent reporter gene. Here, we describe the experimental procedures to carry out in vitro, in vivo and ex vivo studies using these novel bireporter-expressing rVACV, which also represent an excellent option to study the biology of VACV, including the use of these reporter viruses for testing new antivirals and vaccines, using cultured cells and/or well-characterized animal models of infection.

Indexed as

Genes, ReporterVacciniaVaccinia virusAnimalsCell LineDisease Models, AnimalGreen Fluorescent ProteinsHumansLuciferasesMiceGreen Fluorescent ProteinsLuciferasesGFPImagingIn VitroIn VivoLuciferaseNanoLucPoxvirusReporter genesScarletVaccinia virus

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.